Tony Berberabe, MPH

Articles

Partner's Buy-In Key to Minneapolis Urology Group's Success

April 10th 2016

At Metro Urology of Minneapolis, urologists are at the forefront of introducing new techniques and technology, especially with respect to advanced prostate cancer care.

Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types

March 30th 2016

Researchers have designed a recently launched clinical study into entrectinib, a first-in-class inhibitor of tropomyosin receptor kinases, as a basket trial in which the drug can be evaluated simultaneously for activity against three gene alterations and multiple tumor types.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer

March 22nd 2016

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

Quality of Life Scores Similar in Men Undergoing Active Surveillance Versus Those Without Prostate Cancer

March 14th 2016

Men with low-risk prostate cancer who chose active surveillance (AS) reported a higher quality of life than men who chose direct active treatment such as surgery or radiation.

Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials

March 10th 2016

The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).

Secondary Cancers Linked to Radiotherapy in Men With Prostate Cancer

March 9th 2016

Men with prostate cancer treated with radiotherapy were at higher risk for developing second malignancies in the bladder, colon, and rectum compared with men who were not exposed to radiotherapy.

Vitamin D Could Serve as Biomarker for Aggressive Prostate Cancer

March 7th 2016

The level of vitamin D in a patient’s blood could serve as a biomarker for an aggressive form of prostate cancer, especially in men who are considering active surveillance for the disease.

Biomarker-Directed Galeterone Explored in Prostate Cancer Trial

February 24th 2016

Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer

February 23rd 2016

The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.

First Urology of Louisville Enjoys Many Firsts in Technology and Research

February 9th 2016

Being the largest private practice urology center in Kentucky has its advantages, said Ganesh Rao, MD, president of First Urology, PSC, in Louisville.

Durvalumab/Tremelimumab Combo Explored in Lung Cancer Trial

February 5th 2016

With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.

In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim

February 2nd 2016

The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.

Genomic Classifier Refines Risk Calculation After Prostatectomy

February 1st 2016

Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.

Ublituximab Is Combined With Ibrutinib in High-Risk CLL Study

January 13th 2016

Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.

Expert Predicts PD-1/PD-L1 Agents as Backbone of Combination Therapy in RCC

January 6th 2016

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).

Prevalence of DNA Repair Defects Key to Efficacy of PARP Inhibitors in Prostate Cancer

January 6th 2016

Clinical studies suggest that PARP inhibitors are highly efficacious in patients with metastatic castration-resistant prostate cancer with these alternations in DNA repair genes.

Liquid Biopsy Paves Way for Personalized Selection Tool in Prostate Cancer

January 4th 2016

The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.

Prostate Cancer Guidelines Lack Molecular Test Recommendations

December 15th 2015

When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.

Men With High-Risk Prostate Cancer Undergoing More Prostatectomies

December 2nd 2015

Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.

NEXT PAGE
PREVIOUS PAGE